Oruka Therapeutics, Inc. ORKA Unrecognized compensation cost related to non-vested awards

Unrecognized compensation cost related to non-vested awards at other companies

KEE

Keel Infrastructure Corp. Common StockKEEL

$363K—

Rockwell AutomationROK

$76M-24.8%

PepsiCoPEP

$329M-17.3%

MSCIMSCI

$115.5M+10.5%

eBayEBAY

$902M+11.4%

The Travelers CompaniesTRV

$425M+3.7%

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s unrecognized compensation cost related to non-vested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s unrecognized compensation cost related to non-vested awards?: Oruka Therapeutics, Inc. (ORKA) reported unrecognized compensation cost related to non-vested awards of $84.1M in Q1 2026.